Intraperitoneal Chemotherapy: Long-Term Outcomes Revive a Long-Running Debate
A partir de données portant sur 876 patientes atteintes d'un cancer avancé de l'ovaire (durée médiane de suivi : 10,7 ans), cette étude américaine évalue la survie associée à une chimiothérapie intrapéritonéale et identifie divers facteurs associés à un pronostic défavorable
The best clinical trials are thoughtfully designed to address high-priority questions that will improve clinical outcomes for our patients. However, many years can elapse between initial concept, protocol approval, funding, execution, analysis, and presentation. During that time, new targets and predictive markers can emerge, standards may evolve, toxicities are obviated, and scientific-clinical hypotheses become reframed. “Definitive” phase III trials are seldom that, and there are many trials that meet their original primary objective but are not then used to obtain regulatory approval of new interventions or change our standards of care...
Journal of Clinical Oncology , éditorial en libre accès, 2015